Who
Scott L. Burrows
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Spyre Therapeutics; Chief Financial Officer, Arcutis Biotherapeutics.
In numbers
- Trades disclosed
- 106
- Buys
- 0
- Sells
- 20
- Bought
- $0
- Sold
- $17.1M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 1 Apr 2021
- Last trade
- 1 Oct 2026
- Last filed
- 2 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Oct 2026filed 2 Oct 2026 | SYRE Spyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,500 at $0.00 | filing |
| 1 Oct 2026filed 2 Oct 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Code M | $109K7,500 at $14.50 | filing |
| 1 Oct 2026filed 2 Oct 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Sold | $53K600 at $89.07 | filing |
| 1 Oct 2026filed 2 Oct 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Sold | $135K1,500 at $90.27 | filing |
| 1 Oct 2026filed 2 Oct 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Sold | $193K2,100 at $91.92 | filing |
| 1 Oct 2026filed 2 Oct 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Sold | $285K3,071 at $92.95 | filing |
| 1 Oct 2026filed 2 Oct 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Sold | $21K229 at $93.57 | filing |
| 30 Sep 2026filed 2 Oct 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Code M | $254K17,500 at $14.50 | filing |
| 30 Sep 2026filed 2 Oct 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.6M17,500 at $89.89 | filing |
| 30 Sep 2026filed 2 Oct 2026 | SYRE Spyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —17,500 at $0.00 | filing |
| 2 Sep 2026filed 3 Sep 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.6M18,232 at $89.35 | filing |
| 2 Sep 2026filed 3 Sep 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.6M18,232 at $89.35 | filing |
| 1 Sep 2026filed 3 Sep 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Code M | $109K7,500 at $14.50 | filing |
| 1 Sep 2026filed 3 Sep 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Sold | $78K900 at $86.25 | filing |
| 1 Sep 2026filed 3 Sep 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Sold | $382K4,384 at $87.11 | filing |
| 1 Sep 2026filed 3 Sep 2026 | SYRE Spyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,500 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Sold | $177K2,016 at $88.03 | filing |
| 1 Sep 2026filed 3 Sep 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Sold | $18K200 at $89.04 | filing |
| 1 Sep 2026filed 3 Sep 2026 | SYRE Spyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,500 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Code M | $109K7,500 at $14.50 | filing |
News
Financial Review: Intellia Therapeutics (NASDAQ:NTLA) versus Spyre Therapeutics (NASDAQ:SYRE)SYRE · themarketsdaily.com · 19 Oct 2026Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026SYRE · manilatimes.net · 18 Oct 2026
0 headlines in the last 90 days name Scott L. Burrows; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.